This newly published review article offers a comprehensive examination of the complexities of tumour angiogenesis and the origins of endothelial cells (ECs) within tumours. Tumour angiogenesis, a critical process in cancer progression, is characterised by the formation of new blood vessels that sustain tumour growth by supplying oxygen and nutrients. Understanding the diverse sources and mechanisms of endothelial cell development is essential for improving anti-angiogenic therapies, which aim to block blood vessel formation and, consequently, hinder tumour proliferation.

This review delves into the origins of endothelial cells in both normal and tumour angiogenesis, revealing that while normal angiogenesis is typically a structured and regulated process, tumour angiogenesis is notably chaotic and disorganised. Tumour vascular endothelial cells (ECs) arise from various sources, including adjacent ECs, bone marrow-derived endothelial progenitor cells (EPCs), and even cancer stem cells, which can differentiate into endothelial-like cells. Additionally, cancer-associated fibroblasts and immature dendritic cells may transdifferentiate into vascular ECs within the tumour microenvironment.

The article highlights that the dysregulation and heterogeneity of tumour blood vessels complicate the development of effective therapies. Although anti-angiogenic agents have been a pivotal element in cancer treatment, the limited efficacy and resistance of these therapies pose significant challenges. The review outlines the mechanisms of drug resistance, which include adaptive angiogenesis, alternative pathway activation, and genetic heterogeneity within endothelial cells. This resistance often results in the incomplete inhibition of blood vessel growth, allowing tumours to adapt and continue proliferating.

By investigating the molecular signalling pathways involved in tumour angiogenesis, including VEGF, PDGF, FGF, and ANG/Tie2 systems, the article underscores the importance of targeted therapeutic approaches that account for the diverse cellular origins and adaptive mechanisms of tumour endothelial cells. Innovations in therapy must consider the heterogeneous nature of tumour vasculature to overcome resistance and enhance clinical outcomes.

This review offers a nuanced understanding of endothelial cell biology in tumours. By focusing on the origins and adaptive mechanisms of tumour vasculature, it sets the stage for the development of more precise and effective therapeutic strategies to combat cancer.

Source: Compuscript Ltd